Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Next Previous
Trial Profile

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Cabazitaxel (Primary) ; Degarelix (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Radium 223 chloride (Primary) ; Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 02 Nov 2023 Status changed from recruiting to completed.
  • 16 May 2023 Planned primary completion date changed from 28 Apr 2023 to 30 Nov 2023.
  • 17 Apr 2023 Planned number of patients changed from 15000 to 1.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top